Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women ≥ 18 and ≤ 80 years old~2. Subjects must be diagnosed with rheumatoid arthritis for at least 3 months before baseline~3. Active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints at screening and baseline~4. Subjects must be taking MTX for ≥ 12 consecutive weeks and on a stable dose of 7.5 to 25 mg/week for \> 8 weeks prior to receiving the study drug and be willing to remain on stable dose throughout the study~5. Subject has no known history of active tuberculosis~Exclusion Criteria:~1. Class IV RA, Felty's syndrome or history of prosthetic or native joint infection~2. Major chronic inflammatory disease or connective tissue disease other than RA, with the exception of secondary Sjögren's syndrome~3. Prior use of 2 or more biologic therapies for RA~4. Previous receipt of HUMIRA® (adalimumab) or a biosimilar of adalimumab~5. Ongoing use of prohibited treatments~Other Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ABP 501 (Type: EXPERIMENTAL): Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
- Adalimumab (Type: ACTIVE_COMPARATOR): Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).